Latest news

May 30, 2024

Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension

May 28, 2024

Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes

May 09, 2024

Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

X